| Είναι η ιστοσελίδα των γαστρεντερολόγων αλλά και άλλων συναφών ειδικοτήτων.

Η ηωσινοφιλική οισοφαγίτιδα (ΗΟ) είναι μια χρόνια, ανοσολογικής βάσης, διαταραχή του οισοφάγου.

0 687

A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut. 2016 Mar;65(3):390-399

Stephan Miehlke, Petr Hruz, Michael Vieth, Christian Bussmann, Ulrike von Arnim, Monther Bajbouj, Christoph Schlag, Ahmed Madisch, Christiane Fibbe, Henning Wittenburg, Hans Dieter Allescher, Max Reinshagen, Stefan Schubert, Jan Tack, Michaela Müller, Patrick Krummenerl, Joris Arts, Ralph Mueller, Karin Dilger, Roland Greinwald, Alex Straumann

To investigate the efficacy and safety of two different budesonide formulations (effervescent tablet for orodispersible use (BET) and viscous suspension (BVS)) with different daily dosages for short-term treatment of eosinophilic oesophagitis (EoE).

Adults with active EoE (n=76) randomly received 14 days’ treatment with either BET 2×1 mg/day (BET1, n=19) or BET 2×2 mg/day (BET2, n=19), or BVS 2×5 mL (0.4 mg/mL)/day (BVS, n=19) or placebo (n=19) in a double-blind, double-dummy fashion, with a 2-week follow-up. Primary end point was histological remission (mean of

Histological remission occurred in 100%, 94.7% and 94.7% of budesonide (BET1, BET2, BVS, respectively) and in 0% of placebo recipients (p<0.0001). The improvement in total endoscopic intensity score was significantly higher in the three budesonide groups compared with placebo. Dysphagia improved in all groups at the end of treatment; however, improvement of dysphagia persisted only in those treated with BET1 (p=0.0196 vs placebo). There were no serious adverse events. Local fungal infection (stained fungi) occurred in two patients of each budesonide group (10.5%). The effervescent tablet was preferred by 80% of patients.

BET or BVS was highly effective and safe for short-term treatment of EoE. The 1 mg (twice daily) dosage was equally effective as the 2 mg twice daily dosage. The majority of patients preferred the effervescent tablet formulation

Αφήστε μια απάντηση